The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: The predictive role of blood-based tumor mutation burden (bTMB) for selecting advanced nonsmall cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs) is still under debate. Therefore, the purpose of this meta-analysis was to evaluate the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ba, He, Liu, Lei, Peng, Qiang, Chen, Jie, Zhu, Yao-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590772/
https://www.ncbi.nlm.nih.gov/pubmed/34774004
http://dx.doi.org/10.1186/s12885-021-08924-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590772/
https://www.ncbi.nlm.nih.gov/pubmed/34774004
http://dx.doi.org/10.1186/s12885-021-08924-z

Ejemplares similares